Leonardo technology comprises fully biodegradable, porous silicon particles that can be loaded with a diverse array of secondary nanoparticles such as liposomes, micelles, carbon nanotubes, dendrimers and metallic nanoparticles.
Leonardo has formed prototype particles, demonstrating all the necessary unit processes to make the particles.
Under the terms of the agreement, NMS will engineer, refine, and integrate these steps in a manner that prepares Leonardo for manufacturing particles suitable for clinical trials.
NanoMedical Systems president and CEO Randy Goodall said their expertise in the development of drug delivery products would support Leonardo in bringing their manufacturing process to a commercial performance level.